our company
STRIVING TO BE AT THE FOREFRONT OF GLOBAL EFFORTS TO PREVENT AND TREAT DISEASE
FOCUSED ON THE DEVELOPMENT OF NEW BIOLOGICAL TREATMENTS DERIVED FROM AN INNOVATIVE PLANT-BASED PLATFORM
KBio aims to create a new generation of biologics using its plant-based platform, which has demonstrated its ability to produce novel antibody and vaccine candidates with high purityi at a fraction of the time and cost of current technologies. The speed and efficiency demonstrated by the KBio platform has significant potential. The Company is focused on developing novel product candidates in two core areas: 1) Antibody therapies for areas of high unmet need; and 2) Future pandemic preparedness and response.
Launched in January 2022, KBio Holdings Limited (KBio) was created to accelerate the research, development and production of novel treatments.
Discover our story and how we are working to use our plant-based platform and innovative technologies to accelerate the development of new medicines.
2022
Broad Vaccine and mAb therapeutics pipeline in various stages of preclinical and clinical development.
2020
PHASE I CLINICAL TRIALS WITH INVESTIGATIONAL COVID-19 VACCINE CANDIDATE.
2020
PHASE I CLINICAL TRIALS WITH INVESTIGATIONAL QUADRIVALENT FLU VACCINE CANDIDATE.
2015
PRODUCED A MONOCLONAL ANTIBODY PRODUCT INTENDED TO BLOCK SEXUAL TRANSMISSION OF GENITAL HERPES AND HIV FOR A PHASE I Clinical TRIAL IN COLLABORATION WITH Mapp Biopharmaceutical, Inc (MB66).
2014
PRE-CLINICAL EVIDENCE SHOWING THE POTENTIAL FOR OUR VACCINE PLATFORM IN PANDEMIC FLUii.
2014
PRODUCED AN ANTI-EBOLA MONOCLONAL ANTIBODY COCKTAIL ZMAPPTM IN PARTNERSHIP WITH Mapp Biopharmaceutical, Inc , WHICH WAS AUTHORIZED FOR COMPASSIONATE USE BY THE FDA, WENT FROM PROJECT START TO CLINICAL DRUG SUBSTANCE IN UNDER 6 WEEKS.
i Swope K, Morton J, Pogue GP, Burden L, Partain N, Hume S, Shepherd J, Simpson CA, Brennan MB, Furman TC, Kingrey-Gebe S, Martinez T, McDonough J, Pauly MH, Whaley KJ, Zeitlin L, Bratcher B, Haydon H. Reproducibility and flexibility of monoclonal antibody production with Nicotiana benthamiana. MAbs. 2022 Jan-Dec;14(1):2013594. doi: 10.1080/19420862.2021.2013594.PMID: 35000569
ii MALLAJOSYULA, JYOTHI K., ET AL. 2014 10.4161/hv.27567
iii Swope K, Morton J, Pogue GP, Hume S, Pauly M H, Shepherd J, C A, Barry Bratcher 2, Whaley K, Zeitlin L, Davis K, Haydon H. Manufacturing plant-made monoclonal antibodies for research or therapeutic applications. Methods Enzymol. 2021;660:239-263. DOI: 10.1016/bs.mie.2021.05.011